48 -2 (40) 2022 — Musashaykhova Sh.M., Musashaykhov U.Kh., — ANALYSIS OF THE ROLE OF PRO72ARG POLYMORPHISMS OF THE TP53 AND ALR2 GENE (CALR52DEL) WITH THE DEVELOPMENT OF ESSENTIAL THROMBOCYTEMIA

ANALYSIS OF THE ROLE OF PRO72ARG POLYMORPHISMS OF THE TP53 AND ALR2 GENE (CALR52DEL) WITH THE DEVELOPMENT OF ESSENTIAL THROMBOCYTEMIA

Musashaykhova Sh.M., Andijan State Medical Institute.

Musashaykhov U.Kh., Andijan State Medical Institute.

Boboev K.T. Republican Specialized Scientific and Practical Medical Center of Hematology of the Ministry of Health of the Republic of Uzbekistan (RSSPMCH of the Ministry of Health of the Republic of Uzbekistan).

Resume

In 54 patients with ET, the frequency of distribution of alleles and genotypes of Pro72Arg polymorphism in the TP53 and CALR2 (CALR52del) genes was studied. A significant relationship was established between the chance of detecting ET and the positive genotype of CALR2 polymorphism (CALR52del). These data allow us to propose testing of this locus for the diagnosis of ET.

Keywords: genetic polymorphism, TP53 gene Pro72Arg, CALR2, essential thrombocytemia, chronic myeloproliferative disease.

First page

256

Last page

259

For citation: Musashaykhova Sh.M., Musashaykhov U.Kh., Boboev K.T. ANALYSIS OF THE ROLE OF PRO72ARG POLYMORPHISMS OF THE TP53 AND ALR2 GENE (CALR52DEL) WITH THE DEVELOPMENT OF ESSENTIAL THROMBOCYTEMIA //New Day in Medicine 2(40)2022 256-259 https://cutt.ly/dAFetut

LIST OF REFERENCES:

1. Абдулкадыров К.М., Шуваев В.А., Мартынкевич И.С. Миелопролиферативные новообразования /Москва: Литтерра. –  2016. – 304 c.
2. Жигулёва Л.Ю. Научно-организационные основы совершенствования качества медицинской помощи больным с опухолевыми заболеваниями системы крови /Автореферат дисс. докт. мед.наук, СПб. –  2017. –35с.
3. Меликян А.Л., Ковригина А.М., Суборцева И.Н. и соавт. Национальные клинические рекомендации по диагностике и лечению Ph-негативных миелопролиферативных заболеваний (истинной полицитемии, эссенциальной тромбоцитемии, первичного миелофиброза) (редакция 2020 г.) //Клиническая онкогематология. – 2021. – Т.14, № 2. – С. 262–298.  DOI: 10.21320/2500-2139-2021-14-2-262-298
4. Raza S., Viswanatha D., Frederick L. et al. TP53 mutations and polymorphisms in primary myelofibrosis // Am J Hematol. 2012; 87(2): 204–6. doi: 10.1002/ ajh.22216.
5. Саврилова А.М., Ахмадеев А.Р., Хайруллов А.С. Аномалии кариотипа при хронических миелопролиферативных неоплазиях // Практическая медицина. –  2015.–  № 4. – C. 99 –100.
6. Kvasnicka H.M. The differential diagnosis of classical myeloproliferative neoplasms (MPN): the updated WHO criteria // RinshoKetsueki. – 2019. – Vol. 60, №9. – P. 1166-1175.
7. Меликян А.Л., Суборцева И.Н. Классические Рh-негативные миелопролиферативные неоплазии // Клиническая онкогематология. – 2015. – Т. 8,  №2. – С. 201–232.
8. Ortmann C.A., Kent D.G, Nangalia J., et al. Effect of mutation order on myeloproliferative neoplasms // N Engl J Med. 2015; 372(7): 601–12. doi: 10.1056/ NEJMoa1412098.
9. Agarwal  M.B., Malhotra  H., Chakrabarti  P. et  al. Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Indian J Med Paediatr Oncol. 2015; 36:3—16. doi: 10.4103/0971-5851.151770
10. Xiao Z., Chang C.S., Morozova E. et al. Impact of myeloproliferative neoplasms (MPNS) and perceptions of treatment goals amongst physicians and patients in 6 countries: an expansion of the MPN // landmark survey. 2019; 3(s1): 294–5. doi: 10.1097/01.hs9.0000561008.75001.e7.